Human-Derived Lactobacillus Mixture for Fat Absorption Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing obesity treatments, particularly probiotics, are not effective and safe in inhibiting fat absorption and cell differentiation, leading to potential side effects and limited efficacy in reducing body fat.
Innovation Solution
Development of novel Lactobacillus paracasei strain BCC-LP-02 and Lactobacillus plantarum strain BCC-LPL-53, which exhibit reduced fatty acid concentration, exopolysaccharide production, lipase enzyme inhibition, and preadipocyte differentiation inhibition, formulated into compositions for body fat reduction, pharmaceutical, and dietary supplement applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional obesity medications are used to suppress appetite and reduce body fat, then weight loss effect is improved, but side effects such as liver damage, hormonal changes, and weight regain increase
Solution Approach 1:
The patent uses probiotic strains (Lactobacillus paracasei and Lactobacillus plantarum) as temporary, natural microbial agents that can be safely administered without long-term commitment. These probiotics provide weight loss benefits during administration and can be discontinued without causing weight regain or severe side effects, unlike traditional medications that require prolonged use and have serious adverse effects.
Solution Approach 2:
The patent introduces probiotic strains as intermediary substances that mediate between diet and body fat accumulation. The probiotics modulate the gut microbiota, which in turn influences fat absorption and metabolism, providing a gentle, natural pathway for weight loss without the harsh effects of direct pharmaceutical intervention.
2Object-affected harmful factors
If probiotics are used to inhibit fat absorption and cell differentiation, then safety is improved, but effectiveness in reducing body fat is limited
Solution Approach 1:
The patent identifies and utilizes specific probiotic strains (Lactobacillus paracasei and Lactobacillus plantarum) with particular characteristics that enhance their fat-reducing capability. By selecting strains with specific metabolic properties and administering them in optimized conditions, the patent maximizes their effectiveness in inhibiting fat absorption and cell differentiation while maintaining safety.
Solution Approach 2:
The patent combines multiple probiotic strains (Lactobacillus paracasei and Lactobacillus plantarum) to create a synergistic effect that enhances body fat reduction. The composite probiotic formulation leverages the complementary mechanisms of different strains to achieve greater effectiveness than single-strain probiotics while maintaining safety profiles.
3Object-affected harmful factors
If existing probiotic strains are used for body fat reduction, then safety is maintained, but efficacy in inhibiting fat absorption and preadipocyte differentiation is insufficient
Solution Approach 1:
The patent extracts and isolates specific functional characteristics from effective probiotic strains, focusing on their ability to inhibit lipase activity and prevent preadipocyte differentiation. By identifying and emphasizing these specific functional traits in the selected strains, the patent enhances the reliability of fat absorption inhibition while maintaining the safety profile of probiotics.
Data Source
AI summary
The present invention relates to novel lactobacillus mixture compositions having the excellent effect of preventing obesity, and use thereof. More particularly, the present invention relates to lactobacillus mixture compositions comprising Lactobacillusparacasei BCC-LP-02 (accession number KCTC14808BP) strain, and Lactobacillus plantarum BCC-LPL-53 (accession number KCTC 14809BP) strain, and use thereof.